Robert H. Andtbacka, MD, CM, FACS, FRCSC, Seven and Eight Biopharmaceuticals, Edison, NJ, outlines the benefits and recent advances of intratumoral therapy, as well as discussing the effect of toll-like receptor (TLR) agonists in patients with melanoma. Dr Andtbacka also explains the mechanism of action of the TLR7/8 dual agonist, BDB001, and gives an update on the Phase I BDB001-102 trial (NCT04196530) which investigated the combination of intravenous BDB001 with atezolizumab in patients with advanced solid tumors. The trial reported promising results and saw responses in patients with tumors which are refractory to PD-1 and PD-L1 therapies, and saw especially successful results in patients with urothelial carcinoma and non-small cell lung cancer (NSCLC). Many patients also achieved a prolonged stable disease, which is significant for these patients who have undergone multiple previous lines of therapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.